Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 5:45 PM ET

Healthcare Equipment and Supplies

Company Overview of nContact, Inc.

Company Overview

nContact, Inc., a cardiac ablation device company, develops and manufactures medical devices for the minimally invasive treatment of heart arrhythmias in the United States. It develops Numeris coagulation system with VisiTrax, which is indicated for the coagulation of cardiac tissue; and Numeris guided coagulation system, which is used in closed chest procedures, as well as allows the coil end to be maneuvered along a guidewire, through the paracardioscopic cannula, to endoscopically create bi-atrial lesions. The company was formerly known as nContact Surgical, Inc. and changed its name to nContact, Inc. on January 10, 2011. The company was founded in 2005 and is headquartered in Morrisville...

1001 Aviation Parkway

Suite 400

Morrisville, NC 27560

United States

Founded in 2005

Phone:

919-466-9810

Fax:

919-466-9811

Key Executives for nContact, Inc.

Chief Executive Officer
Age: 54
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Development & Operations
Vice President of Finance
Compensation as of Fiscal Year 2015.

nContact, Inc. Key Developments

nContact Appoints William Hawkins as Chairman of its Board of Directors

nContact announced that William (Bill) Hawkins has been appointed as Chairman of its Board of Directors. Bill Hawkins has served as a special advisor to the nContact Board since 2013 and is a veteran entrepreneur and executive in the medical device arena, with more than 20 years of C-Suite experience in cardiology, surgery, and vascular therapies. Most recently, Bill was President and CEO of Immucor.

nContact Secures $20 Million in Growth Capital Financing

nContact announced that it has entered into a $20 million growth capital financing agreement with Hercules Technology Growth Capital, Inc. The company plans to use this financing to support its ongoing CONVERGE IDE Clinical Trial, expand its field support teams, and further next-generation product development. The randomized CONVERGE IDE clinical trial is the first head-to-head study comparing the multidisciplinary Convergent Procedure to traditional catheter ablation in the treatment of persistent AF. AF is the most common arrhythmia, affecting 15 million people in the western world, with an estimated 88% falling into the difficult-to-treat persistent AF population. The CONVERGE clinical trial randomizes patients 2:1 between the epicardial-endocardial Convergent Procedure and endocardial-only ablation with fluid-irrigated catheters.

nContact, Inc. Announces First Patient Treated in the CONVERGE IDE Clinical Trial

nContact, Inc. announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.

Similar Private Companies By Industry

Company Name Region
Orthoworld, LLC United States
No-Fade Coatings, Inc. United States
Ortho Organizers, Inc. United States
Tensegrity Technologies Inc. United States
Ivoclar Vivadent Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 12, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact nContact, Inc., please visit www.ncontact.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.